HeartBeam Inc

HeartBeam Inc. reports Q4 2025 earnings: improved quarterly losses, full‑year loss still high, FDA clearances pave way for tele‑cardiac services launch.

HeartBeam Inc. reports Q3 2025 earnings: $0.9 M revenue, loss narrowed to $0.129 EPS, and guidance points to continued growth in tele‑cardiac care.

HeartBeam Inc. expands its patent portfolio and strengthens its leadership with new appointments, positioning the company for growth in the telemedicine sector.

HeartBeam Inc. has made a strategic move to bolster commercialization efforts by appointing its CEO to the board, aiming to accelerate the company’s telemedicine solutions for cardiac care and improve its market presence.

HeartBeam Inc. has expanded its leadership by appointing its CEO as a director, aiming to strengthen leadership and decision-making as the company continues to grow in the healthcare sector.

HeartBeam Inc. has made significant strides in telemedicine, particularly in cardiac care, with its ECG software demonstrating promising results in a clinical study and its synthesized 12-lead ECG technology meeting clinical endpoints in a pivotal study.